慢性乙型肝炎患者治疗前后肝活检纤维化评估的新分类
该研究提出一种评估肝纤维化质量动态变化的新分类,将纤维化分为进展为主、消退为主和不确定三类,并应用于71对慢性乙型肝炎患者恩替卡韦治疗78周前后的肝活检。治疗后消退为主者从13%升至78%,55例消退为主者中29例Ishak分期改善至少1期,25例Ishak分期不变但Laennec亚分期、胶原面积百分比和肝硬度显著改善。
要点
- 新分类按纤维化质量动态分为进展为主、消退为主和不确定三类。
- 恩替卡韦治疗78周后消退为主者由13%升至78%。
- 55例消退为主者中25例Ishak分期不变但Laennec亚分期等显著改善。
核心结论
- 新分类强调评估和识别纤维化质量动态变化的重要性,在抗病毒治疗时代尤其 relevant。
研究设计与样本
- 研究纳入71对慢性乙型肝炎患者治疗前后的配对肝活检,治疗为以恩替卡韦为基础、持续78周。
主要发现
- 治疗前进展为主、不确定和消退为主分别占58%、29%和13%,治疗后分别占11%、11%和78%。
- 55例治疗后肝活检显示消退为主变化的患者中,29例(53%)纤维化改善至少一个Ishak分期。
- 55例中25例(45%)虽仍处于同一Ishak分期,但Laennec亚分期、胶原百分比面积和肝硬度均有显著改善。
关键数值与推荐
- 进展为主:纤维间隔厚/宽/疏松/苍白伴炎症;消退为主:纤维间隔纤细/薄/致密/分裂;不确定:进展性与消退性瘢痕总体平衡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Liver fibrosis is the net result of dynamic changes between fibrogenesis and fibrolysis. Evidence has shown that antiviral therapy can reverse liver fibrosis or even early cirrhosis caused by hepatitis B virus. However, current evaluation systems mainly focus on the severity of, but not the dynamic changes in, fibrosis. Here, we propose a new classification to evaluate the dynamic changes in the quality of fibrosis, namely: predominantly progressive (thick/broad/loose/pale septa with inflammation); predominately regressive (delicate/thin/dense/splitting septa); and indeterminate, which displayed an overall balance between progressive and regressive scarring. Then, we used this classification to evaluate 71 paired liver biopsies of chronic hepatitis B patients before and after entecavir-based therapy for 78 weeks. Progressive, indeterminate, and regressive were observed in 58%, 29%, and 13% of patients before treatment versus in 11%, 11%, and 78% after treatment. Of the 55 patients who showed predominantly regressive changes on posttreatment liver biopsy, 29 cases (53%) had fibrosis improvement of at least one Ishak stage, and, more interestingly, 25 cases (45%) had significant improvement in terms of Laennec substage, collagen percentage area, and liver stiffness despite remaining in the same Ishak stage. CONCLUSION: This new classification highlights the importance of assessing and identifying the dynamic changes in the quality of fibrosis, especially relevant in the era of antiviral therapy.(Hepatology 2017;65:1438-1450).
引用
- Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017. PMID: 28027574. doi:10.1002/hep.29009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。